(Reuters) - Gross sales of Bristol-Myers Squibb Co's most cancers drug Abraxane have been suspended in China based mostly on findings at a third-party manufacturing plant in the USA.
The suspension by the China Nationwide Medical Merchandise Administration was introduced by associate Beigene Ltd and confirmed by Bristol-Myers on Wednesday.
Beigene and Bristol-Myers have been working to revive provide as quickly as potential, stated China-based Beigene, which signed an settlement with Bristol-Myers' Celgene unit in 2017 to market and distribute Abraxane.
"This choice solely applies to the China market and doesn't impression our capacity to provide Abraxane outdoors of China," Bristol-Myers stated in an emailed assertion.
The drug introduced in gross sales of $1.2 billion for Bristol-Myers in 2019.
Together with remediation efforts on the U.S. website, Bristol-Myers has utilized for approval to supply its provide of Abraxane for the China market from an alternate manufacturing facility, Beigene stated.
(This story corrects to "plant" from "pant" in paragraph 1)
(Reporting by Manas Mishra in Bengaluru; Modifying by Shinjini Ganguli and Vinay Dwivedi)